What is HC Wainwright’s Estimate for PSTV FY2028 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Analysts at HC Wainwright issued their FY2028 EPS estimates for Plus Therapeutics in a research note issued on Friday, November 15th. HC Wainwright analyst S. Lee anticipates that the company will post earnings per share of $0.28 for the year. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.00) per share.

Separately, Ascendiant Capital Markets dropped their price target on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd.

Plus Therapeutics Trading Up 2.5 %

Shares of NASDAQ:PSTV opened at $1.22 on Monday. The firm’s 50 day moving average is $1.40 and its two-hundred day moving average is $1.66. Plus Therapeutics has a 52 week low of $1.15 and a 52 week high of $2.67. The firm has a market capitalization of $7.20 million, a P/E ratio of -0.48 and a beta of 0.69.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics at the end of the most recent reporting period. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.